Panbela Therapeutics Analyst Ratings
Panbela Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/24/2023 | 672.95% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy |
| 07/10/2023 | 672.95% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 06/13/2023 | 672.95% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 06/02/2023 | 672.95% | HC Wainwright & Co. | $7 → $16 | Reiterates | → Buy |
| 05/05/2023 | 238.16% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 04/26/2023 | 238.16% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 03/20/2023 | -27.54% | Maxim Group | → $1.5 | Upgrades | Hold → Buy |
| 01/31/2023 | 383.09% | Roth Capital | → $10 | Reinstates | → Buy |
| 10/12/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 06/28/2021 | 383.09% | Roth Capital | → $10 | Initiates Coverage On | → Buy |
| 03/10/2021 | 286.47% | Maxim Group | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 07/24/2023 | 672.95% | HC Wainwright公司 | $16→$16 | 重申 | 购买→购买 |
| 07/10/2023 | 672.95% | HC Wainwright公司 | →$16 | 重申 | 购买→购买 |
| 2023/06/13 | 672.95% | HC Wainwright公司 | →$16 | 重申 | 购买→购买 |
| 06/02/2023 | 672.95% | HC Wainwright公司 | $7→$16 | 重申 | →购买 |
| 05/05/2023 | 238.16% | HC Wainwright公司 | →$7 | 重申 | →购买 |
| 04/26/2023 | 238.16% | HC Wainwright公司 | →$7 | 开始承保 | →购买 |
| 03/20/2023 | -27.54% | Maxim集团 | →$1.5 | 升级 | 持有→购买 |
| 2023年1月31日 | 383.09% | 罗斯资本 | →$10 | 恢复 | →购买 |
| 10/12/2022 | - | Maxim集团 | 评级下调 | 购买→Hold | |
| 2021/06/28 | 383.09% | 罗斯资本 | →$10 | 开始承保 | →购买 |
| 03/10/2021 | 286.47% | Maxim集团 | →$8 | 开始承保 | →购买 |
What is the target price for Panbela Therapeutics (PBLA)?
Panbela治疗公司(PBLA)的目标价格是多少？
The latest price target for Panbela Therapeutics (NASDAQ: PBLA) was reported by HC Wainwright & Co. on July 24, 2023. The analyst firm set a price target for $16.00 expecting PBLA to rise to within 12 months (a possible 672.95% upside). 9 analyst firms have reported ratings in the last year.
潘贝拉治疗公司(纳斯达克：PBLA)的最新目标价是由HC Wainwright&Co.于2023年7月24日报道的。这家分析公司将目标价定为16美元，预计PBLA将在12个月内升至(可能上涨672.95%)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Panbela Therapeutics (PBLA)?
Panbela治疗公司(PBLA)的最新分析师评级是多少？
The latest analyst rating for Panbela Therapeutics (NASDAQ: PBLA) was provided by HC Wainwright & Co., and Panbela Therapeutics reiterated their buy rating.
潘贝拉治疗公司(纳斯达克代码：PBLA)的最新分析师评级由HC Wainwright&Co.提供，潘贝拉治疗公司重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Panbela Therapeutics (PBLA)?
Panbela治疗公司(PBLA)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Panbela Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Panbela Therapeutics was filed on July 24, 2023 so you should expect the next rating to be made available sometime around July 24, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Panbela治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Panbela治疗公司的上一次评级是在2023年7月24日提交的，所以你应该预计下一次评级将在2024年7月24日左右的某个时候提供。
Is the Analyst Rating Panbela Therapeutics (PBLA) correct?
分析师对Panbela Treeutics(PBLA)的评级正确吗？
While ratings are subjective and will change, the latest Panbela Therapeutics (PBLA) rating was a reiterated with a price target of $16.00 to $16.00. The current price Panbela Therapeutics (PBLA) is trading at is $2.07, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Panbela治疗(PBLA)评级被重申，目标价在16.00美元至16.00美元之间。Panbela治疗公司(PBLA)目前的交易价格为2.07美元，超出了分析师的预测范围。